Posts Tagged ‘crohns disease’

Ustekinumab for Crohn’s Disease

Posted by • November 17th, 2016

In a previous phase 2b trial, intravenous ustekinumab induction therapy in patients with Crohn’s disease that was refractory to treatment with tumor necrosis factor (TNF) antagonists showed a significant benefit in terms of clinical response but not remission, and subcutaneously administered maintenance doses of ustekinumab were efficacious during a period of 22 weeks. Feagan et… Read More…

A Man with an Ileocecal Mass

Posted by • March 11th, 2016

Misdiagnosis of Crohn’s disease in a patient with intestinal tuberculosis would generally result in treatment with glucocorticoids and biologic agents, which then has the potential to cause disease progression that leads to increased morbidity and mortality. A new Case Record summarizes. An 80-year-old man presented with anorexia, weight loss, abdominal pain, diarrhea, and an ileocecal mass. 18F-fluorodeoxyglucose… Read More…

Watch the Latest NEJM Quick Takes

Posted by • March 18th, 2015

There may be important new progress in the treatment of Crohn’s Disease. Watch the 1-minute Quick Take video summary of the phase 2 trial of Mongersen, an oligonucleotide that interferes with a signaling pathway involved in the pathogenesis of Crohn’s Disease. Also, read the full article and editorial. Watch other recent video summaries, including: CABG vs… Read More…

TNF Inhibitors for Inflammatory Bowel Disease

Posted by • August 23rd, 2013

In the latest review article in our Clinical Therapeutics series, a 35-year-old man presents with an exacerbation of Crohn’s disease. Treatment with a TNF inhibitor is recommended. TNF inhibitors block the effects of the proinflammatory cytokine TNF-α, and several have been shown to be effective in treating inflammatory bowel disease. Inflammatory bowel disease, an umbrella term… Read More…

Vedolizumab Therapy for Ulcerative Colitis and Crohn’s Disease

Posted by • August 21st, 2013

A friend of mine, who has spent 15 years dealing with the ebbs and flows of ulcerative colitis (UC), is the kind of patient who would hope her physician pays attention to the results of two RCTs published this week in NEJM. She is one of an estimated 1.4 million Americans diagnosed with UC or… Read More…

Natalizumab-Associated PML

Posted by • May 16th, 2012

A new study found that in patients treated with natalizumab, PML incidence was about 11 cases per 1000 patients with 25 to 48 months of treatment, prior immunosuppressant use, and anti–JC virus antibody–positive status. The incidence was estimated to be 0.09 cases or fewer per 1000 antibody-negative patients. Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) is approved… Read More…

Ulcerative Colitis

Posted by • November 4th, 2011

Ulcerative colitis is the most common form of inflammatory bowel disease. Its course is often mild, with few complications, and it can be cured by colectomy. Our current understanding of its pathophysiology, diagnosis, and treatment is reviewed in a new Medical Progress article. Ulcerative colitis is the most common form of inflammatory bowel disease worldwide. In… Read More…